文献速递前列腺癌泌尿系感染

经会阴与经直肠磁共振成像靶向及系统穿刺活检预防感染并发症的比较:PREVENT随机试验

Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.
PubMed 文献 · Eur Urol · 2024-01-11

多中心随机试验将658例初次活检参与者分配至无抗生素预防的经会阴活检组或靶向预防的经直肠活检组,主要终点为活检后感染。经会阴组感染0例,经直肠组4例(1.4%),差异未达统计学显著(p=0.059)。两组临床显著前列腺癌检出率相似,经会阴组围术期疼痛略差但7天内缓解。

要点

  • 经会阴组活检后感染0例,经直肠靶向预防组4例(1.4%),差异未达统计学显著(p=0.059)。
  • 临床显著前列腺癌检出率经会阴组53% vs 经直肠组50%,校正差异2.0%(95%CI -6.0, 10)。
  • 经会阴组围术期疼痛评分校正差异0.6分(0-10量表,95%CI 0.2, 0.9),7天时缓解。

核心结论

  • 诊室经会阴活检可耐受、不降低癌症检出率,且未导致感染并发症。
  • 经直肠活检联合靶向预防达到相似的感染率,但需要直肠拭子培养并仔细关注抗生素选择与给药。
  • 作者认为应考虑上述因素和抗生素管理来指导临床决策。

研究设计与样本

  • 多中心随机试验,将初次活检参与者分配至无抗生素预防的经会阴活检组或靶向预防的经直肠活检组。
  • 靶向预防指直肠拭子培养筛查氟喹诺酮类耐药菌,并根据培养和药敏结果选择抗生素。
  • 共658例参与者被随机分配。
  • 主要终点为活检后感染,通过前瞻性病历审查和患者7天调查问卷报告捕获。
  • 次要终点包括癌症检出、非感染性并发症以及活检期间和活检后7天活检相关疼痛与不适的数字评定量表(0-10)评分。

主要发现

  • 经会阴组感染0例 vs 经直肠组4例(1.4%),差异-1.4%(95%CI -3.2%, 0.3%;p=0.059)。
  • 其他并发症发生率很低且两组相似。
  • 临床显著前列腺癌检出率经会阴组53% vs 经直肠组50%,校正差异2.0%(95%CI -6.0, 10)。
  • 经会阴组围术期疼痛更差,校正差异0.6分(0-10量表,95%CI 0.2, 0.9),但效应小且7天时缓解。

临床怎么用

  • 作者认为诊室经会阴活检可耐受、不降低癌症检出率且未导致感染并发症。
  • 作者指出经直肠活检联合靶向预防达到相似感染率,但需要直肠拭子培养并仔细关注抗生素选择与给药。
  • 作者认为应考虑上述因素和抗生素管理来指导临床决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The transrectal biopsy approach is traditionally used to detect prostate cancer. An alternative transperineal approach is historically performed under general anesthesia, but recent advances enable transperineal biopsy to be performed under local anesthesia. We sought to compare infectious complications of transperineal biopsy without antibiotic prophylaxis versus transrectal biopsy with targeted prophylaxis. METHODS: We assigned biopsy-naïve participants to undergo transperineal biopsy without antibiotic prophylaxis versus transrectal biopsy with targeted prophylaxis (rectal culture screening for fluoroquinolone-resistant bacteria and antibiotic targeting to culture and sensitivity results) through a multicenter, randomized trial. The primary outcome was post-biopsy infection captured by a prospective medical review and patient report on a 7-d survey. The secondary outcomes included cancer detection, noninfectious complications, and a numerical rating scale (0-10) for biopsy-related pain and discomfort during and 7-d after biopsy. KEY FINDINGS AND LIMITATIONS: A total of 658 participants were randomized, with zero transperineal versus four (1.4%) transrectal biopsy infections (difference -1.4%; 95% confidence interval [CI] -3.2%, 0.3%; p = 0.059). The rates of other complications were very low and similar. Importantly, detection of clinically significant cancer was similar (53% transperineal vs 50% transrectal, adjusted difference 2.0%; 95% CI -6.0, 10). Participants in the transperineal arm experienced worse periprocedural pain (0.6 adjusted difference [0-10 scale], 95% CI 0.2, 0.9), but the effect was small and resolved by 7-d. CONCLUSIONS AND CLINICAL IMPLICATIONS: Office-based transperineal biopsy is tolerable, does not compromise cancer detection, and did not result in infectious complications. Transrectal biopsy with targeted prophylaxis achieved similar infection rates, but requires rectal cultures and careful attention to antibiotic selection and administration. Consideration of these factors and antibiotic stewardship should guide clinical decision-making. PATIENT SUMMARY: In this multicenter randomized trial, we compare prostate biopsy infectious complications for the transperineal versus transrectal approach. The absence of infectious complications with transperineal biopsy without the use of preventative antibiotics is noteworthy, but not significantly different from transrectal biopsy with targeted antibiotic prophylaxis.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hu JC, Assel M, Allaf ME, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024. PMID: 38212178. doi:10.1016/j.eururo.2023.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。